Generalized metabolic bone disease in Neurofibromatosis type I

Molecular Genetics and Metabolism

Volumn 94, Issue 1, 2008, Pages 105-111

  Brunetti Pierri, Nicola ^a   Doty, Stephen B ^b   Hicks, John ^a   Phan, Kelly ^a   Mendoza Londono, Roberto ^a   Blazo, Maria ^a   Tran, Alyssa ^a   Carter, Susan ^a   Lewis, Richard Alan ^a   Plon, Sharon E ^a   Phillips, William A ^a   O'Brian Smith, E ^a   Ellis, Kenneth J ^a   Lee, Brendan ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Neurofibromatosis type I; NF1; Osteopenia; Osteoporosis

Indexed keywords

CALCIUM; CALCIUM PHOSPHATE; VITAMIN D;

ADOLESCENT; ADULT; ARTICLE; BIOCHEMISTRY; BONE DENSITY; BONE MASS; BONE TURNOVER; CALCIUM METABOLISM; CHILD; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DENSITOMETRY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERPARATHYROIDISM; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; METABOLIC BONE DISEASE; NEUROFIBROMATOSIS; PHOSPHATE METABOLISM; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TRABECULAR BONE;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 1; PARATHYROID HORMONE;

EID: 41949098157     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2007.12.004     Document Type: Article

References (30)

1. Friedman J.M. Epidemiology of neurofibromatosis type 1. Am. J. Med. Genet. 89 (1999) 1-6
2. Carey J.C., and Viskochil D.H. Neurofibromatosis type 1: a model condition for the study of the molecular basis of variable expressivity in human disorders. Am. J. Med. Genet. 89 (1999) 7-13
3. Crawford Jr. A.H., and Bagamery N. Osseous manifestations of neurofibromatosis in childhood. J. Pediatr. Orthop. 6 (1986) 72-88
4. Riccardi V.M. Von Recklinghausen neurofibromatosis. N. Engl. J. Med. 305 (1981) 1617-1627
5. Stevenson D.A., Zhou H., Ashrafi S., Messiaen L.M., Carey J.C., D'Astous J.L., Santora S.D., and Viskochil D.H. Double inactivation of NF1 in tibial pseudarthrosis. Am. J. Hum. Genet. 79 (2006) 143-148
6. Alwan S., Tredwell S.J., and Friedman J.M. Is osseous dysplasia a primary feature of neurofibromatosis 1 (NF1)?. Clin. Genet. 67 (2005) 378-390
7. Illes T., Halmai V., de Jonge T., and Dubousset J. Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities. Osteoporos. Int. 12 (2001) 823-827
8. Yilmaz K., Ozmen M., Bora Goksan S., and Eskiyurt N. Bone mineral density in children with neurofibromatosis 1. Acta Paediatr. 96 (2007) 1220-1222
9. Lammert M., Kappler M., Mautner V.F., Lammert K., Storkel S., Friedman J.M., and Atkins D. Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos. Int. 16 (2005) 1161-1166
10. Stevenson D.A., Moyer-Mileur L.J., Murray M., Slater H., Sheng X., Carey J.C., Dube B., and Viskochil D.H. Bone mineral density in children and adolescents with neurofibromatosis type 1. J. Pediatr. 150 (2007) 83-88
11. Kuorilehto T., Poyhonen M., Bloigu R., Heikkinen J., Vaananen K., and Peltonen J. Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos. Int. 16 (2005) 928-936
12. Dulai S., Briody J., Schindeler A., North K.N., Cowell C.T., and Little D.G. Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort. J. Pediatr. Orthop. 27 (2007) 472-475
13. Writing Group for the ISCD Position Development Conference. Diagnosis of osteoporosis in men, premenopausal women, and children. J. Clin. Densitom. 7 (2004) 17-26.
14. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch. Neurol. 45 (1988) 575-578.
15. Angus R.M., Sambrook P.N., Pocock N.A., and Eisman J.A. A simple method for assessing calcium intake in Caucasian women. J. Am. Diet. Assoc. 89 (1989) 209-214
16. Bertelloni S., Baroncelli G.I., Battini R., Perri G., and Saggese G. Short-term effect of testosterone treatment on reduced bone density in boys with constitutional delay of puberty. J. Bone Miner. Res. 10 (1995) 1488-1495
17. Ellis K.J., Shypailo R.J., Hardin D.S., Perez M.D., Motil K.J., Wong W.W., and Abrams S.A. Z score prediction model for assessment of bone mineral content in pediatric diseases. J. Bone Miner. Res. 16 (2001) 1658-1664
18. Szudek J., Birch P., and Friedman J.M. Growth charts for young children with neurofibromatosis 1 (NF1). Am. J. Med. Genet. 92 (2000) 224-228
19. Vitale M.G., Guha A., and Skaggs D.L. Orthopaedic manifestations of neurofibromatosis in children: an update. Clin. Orthop. (2002) 107-118
20. Bass S., Delmas P.D., Pearce G., Hendrich E., Tabensky A., and Seeman E. The differing tempo of growth in bone size, mass, and density in girls is region-specific. J. Clin. Invest. 104 (1999) 795-804
21. Bonnick S. Bone densitometry in clinical practice (1998), Humana Press Inc., Totowa (NJ) pp. 31-64
22. Gluer C.C., Faulkner K.G., Estilo M.J., Engelke K., Rosin J., and Genant H.K. Quality assurance for bone densitometry research studies: concept and impact. Osteoporos. Int. 3 (1993) 227-235
23. Thomas M.K., Lloyd-Jones D.M., Thadhani R.I., Shaw A.C., Deraska D.J., Kitch B.T., Vamvakas E.C., Dick I.M., Prince R.L., and Finkelstein J.S. Hypovitaminosis D in medical inpatients. N. Engl. J. Med. 338 (1998) 777-783
24. Vieth R., Chan P.C., and MacFarlane G.D. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am. J. Clin. Nutr. 73 (2001) 288-294
25. Andersen L.B., Fountain J.W., Gutmann D.H., Tarle S.A., Glover T.W., Dracopoli N.C., Housman D.E., and Collins F.S. Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat. Genet. 3 (1993) 118-121
26. Johnson M.R., Look A.T., DeClue J.E., Valentine M.B., and Lowy D.R. Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTPRas. Proc. Natl. Acad. Sci. USA 90 (1993) 5539-5543
27. The I., Murthy A.E., Hannigan G.E., Jacoby L.B., Menon A.G., Gusella J.F., and Bernards A. Neurofibromatosis type 1 gene mutations in neuroblastoma. Nat. Genet. 3 (1993) 62-66
28. Coen G. Adynamic bone disease: an update and overview. J. Nephrol. 18 (2005) 117-122
29. Kolanczyk M., Kossler N., Kuhnisch J., Lavitas L., Stricker S., Wilkening U., Manjubala I., Fratzl P., Sporle R., Herrmann B.G., Parada L.F., Kornak U., and Mundlos S. Multiple roles for neurofibromin in skeletal development and growth. Hum. Mol. Genet. 16 (2007) 874-886
30. Yang F.C., Chen S., Robling A.G., Yu X., Nebesio T.D., Yan J., Morgan T., Li X., Yuan J., Hock J., Ingram D.A., and Clapp D.W. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J. Clin. Invest. 116 (2006) 2880-28891